NEWS: Chimeron Bio Launches Vaccine Program for COVID-19

Combining our first-in-class platform & the science of synthetic genomics to transform RNA therapy.

Chimeron Bio is building a portfolio of self-amplifying RNA therapeutics to bring more effective gene therapies and personalized medicines to patients.

Explore Our Pipeline

How we do it

Our ChaESAR Platform

Chimeron Bio’s unique ChaESAR platform leverages chimera encased self-amplifying RNA (saRNA) to achieve superior expression and broader dynamic range compared to other leading messenger RNA (mRNA) technologies.

Learn How

Why we do it

Building on the Modern Science of RNA to Create First-in-Class saRNA Drugs for Patients with Unmet Needs

We are developing a compelling portfolio of innovative and personalized saRNA-based medicines for people with serious diseases including cancer, infectious diseases, and rare genetic disorders, using our technology to achieve superior patient response at a lower dose.

About the Science Explore Our Pipeline

rna cancer infectious disease rare genetic disorders
curve seperator

The Latest from Chimeron Bio

In the News

April 2, 2020

A Message from the CEO on the COVID-19 Initiative

Chimeron Bio's CEO Dr. Jolly Mazumdar speaks in more detail about the company's COVID-19 vaccine program.

From Our Blog

February 12, 2020

Tackling Polygenic Diseases – Chimeron Bio’s Combination RNA Drug Platform is Pushing the Field

See how ChaESAR particles are designed to & can package multiple genes & RNA types (mRNA, small oligos) within the same particle & maintain tissue tropism.

passionate about science

Are you passionate about science and making an impact?

We’re looking for talented individuals to join our team.

Explore Careers